Novel In Vitro Granuloma Model for Studying Tuberculosis and Drug Efficacy


CDC researchers have developed an in vitro model system designed to simulate early-stage Mycobacterium tuberculosis infection and induced granuloma formation. This modeling platform can be used for studying tuberculosis pathogenicity, identifying phenotypically-interesting clinical isolates, studying early-stage host cytokine/chemokine responses, and in vitro candidate-drug screening. The approach incorporates autologous human macrophages, human peripheral blood mononuclear cells, and mycobacteria to mimic in situ granuloma formation in a controllable in vitro environment. This technology would be broadly useful for investigations into the numerous facets of early granuloma host-pathogen interaction, ultimately leading to improved prevention, intervention, and treatment strategies.

Potential Commercial Applications: Competitive Advantages:
  • In vitro modeling system
  • Basic research into tuberculosis-host interactions
  • Drug candidate screening
 
  • Low-cost alternative for modeling mycobacterial infections within complex tissue systems
  • Allows researchers to examine early-stage granuloma formation in a highly controllable, human-based modeling system
  • Cost-effective screening of potential therapeutic compounds and/or phenotypically-interesting mycobacteria


Development Stage:
  • In vitro data available
  • Prototype


Inventors:

Manon Deslauriers (CDC)  ➽ more inventions...

Kristin Birkness (CDC)  ➽ more inventions...

Frederick Quinn (CDC)  ➽ more inventions...

Peter King (CDC)  ➽ more inventions...


Intellectual Property:
U.S. Pat: 7,105,170 issued 2006-09-12
PCT Application No. PCT/US2002/000309
US Application No. 10/250,930
Various international patents issued or pending

Publications:
Birkness KA, et al. PMID 17199112

Licensing Contact:
Jeremiah Mitzelfelt,
Email: jeremiah.mitzelfelt@nih.gov
Phone: 301-443-8518

OTT Reference No: E-249-2013/0
Updated: Feb 7, 2014